An algorithm for guiding clinical judgments about the futility of anti-VEGF treatment of neovascular age-related macular degeneration (nvAMD) has importance from clinical, ethical, and legal perspectives and would be a valuable decision-making tool for retina specialists and payors, according to David T. Wong, MD.
There are a number of ongoing clinical trials investigating treatments for dry age-related macular degeneration (AMD). These modalities include medications that are already in use for other indications and investigational agents representing various novel mechanisms of action.
Photorefractive keratectomy (PRK) was the original excimer laser procedure approved by the FDA—and is still a safe and effective treatment of refractive errors. PRK has the benefits of no-flap creation; therefore, there is no risk of flap complications.
Glaucoma drainage devices aid in controlling IOP by redirecting aqueous from the anterior chamber to an external reservoir to regulate flow. While effective, they are traditionally anchored through the use of sutures, which is both time-intensive and may cause complications.
New technology has been paired with the time-tested technique of direct ophthalmoscopy to create a portable, retinal imaging system (D-Eye, D-Eye S.r.l.) that utilizes a small optical device magnetically attached to a smartphone.
Recently, evidence has been accumulating to support the theory that cerebrospinal fluid pressure (CSFp) is also important in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG), and the relationship has potential implications for clinical practice, said R. Rand Allingham, MD.
Cataract surgery in patients with coexisting uveitis is more challenging than managing either condition alone. Surgeons must answer a different set of questions and consider alternative management strategies, said Debra A. Goldstein, MD, FRSC, professor of ophthalmology and director of the Uveitis Service, Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago.
When I was a resident at the SUNY College of Optometry, I was asked a to conduct a few patient question and answer sessions regarding glaucoma. The sessions consisted of me sitting with a small group of patients, family members, or whoever wanted to know more about glaucoma.